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S U M M A R Y
Objectives: In the USA, tuberculosis disease rates are highest in older adults. Diagnostic testing for latent
tuberculosis infection (LTBI) has not been evaluated carefully in this group. The aim of this study was to
deﬁne the relationship between tuberculin skin test (TST) results, T-SPOT.TB results, and T-cell responses
to Mycobacterium tuberculosis antigens.
Methods: Long-term care facility residents with known prior TST results (positive or negative) were
retested with TSTs and T-SPOT.TB. Prior exposure to M. tuberculosis was assessed by quantifying T-cell
activation to mycobacterial antigens in vitro.
Results: The median age of the 37 participants was 77 years (range 57–98 years). Among 18 participants
with a prior positive TST, three (16.7%) had a negative TST when retested (TST reversion); two had a
negative T-SPOT.TB. Of the 15 who were historically and currently TST-positive, four (26.7%) had a
negative T-SPOT.TB and one (6.7%) had a borderline result. Percentages of CD4+ T-cells responding to
mycobacterial antigens were higher in participants with positive TST and T-SPOT.TB (18.2%) compared to
those with a positive TST but negative T-SPOT.TB (6.4%, p = 0.16) and negative TST and T-SPOT.TB (5.9%,
p < 0.001).
Conclusions: LTBI testing in older adults is complicated by TST reversion and TST-positive/T-SPOT.-
TB-negative discordance, which may reﬂect clearance of infection or waning immunity.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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An estimated 32% of the world’s population, or 1.86 billion
people, are infected with Mycobacterium tuberculosis,1 and more
than eight million new cases of tuberculosis disease (TB) occur
each year.2 Between 1993 and 2008, 21.9% of TB cases in the USA
involved older adults (65 years of age),3 so continued progress
towards the elimination of TB in the USA will require that the
substantial burden of TB in older adults is addressed. Average
yearly TB rates between 1993 and 2008 were 1.5 times higher in
older adults than in those aged 21–64 years and were 2.3 times
higher in older adults residing in long-term care facilities (LTCF)
than in those in the community.3 Older adults comprise the fastest* Corresponding author. Tel.: +1 617 638 7781; fax: +1 617 414 7062.
E-mail address: nhoch@bu.edu (N.S. Hochberg).
http://dx.doi.org/10.1016/j.ijid.2016.01.007
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).growing sector of the global population and are expected to
account for 20% of the US population by the year 2050.4 The
population of older adults in need of long-term care is predicted to
rise from eight million in 2000 to 19 million in 2050.5 Because most
TB in older adults likely results from reactivation of latent TB
infection (LTBI) rather than new infection,6,7 accurate diagnosis of
LTBI in this population is critical, particularly if linked to the
treatment of LTBI.
Diagnosing LTBI in older adults is complicated because of the
limited speciﬁcity of the tuberculin skin test (TST) and reversion
over time. TSTs are known to have reduced speciﬁcity among
persons with non-tuberculous mycobacterial exposure, those with
a history of residence in the southern USA, and bacillus Calmette–
Gue´rin (BCG)-vaccinated individuals.8–11 The use of boosted (two-
step) TSTs, recommended for LTCF residents,6,9 further reduces test
speciﬁcity; a study from Hong Kong showed that boosted TST
results are not predictive of TB disease.12 The sensitivity of the TSTciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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with a 5% decline in test positivity per decade after age 65 years, up
to 9% annually in those >60 years of age.14,16 Comorbidities
associated with older age, including being malnourished or
underweight12 and requiring assisted feeding,14 can also reduce
TST sensitivity. What is unknown is the degree to which the
waning TST response reﬂects cleared infection and to what degree
the waning TST response reﬂects a false-negative test.
Data on the use of interferon-gamma release assays (IGRAs),
including the T-SPOT.TB and QuantiFERON-TB Gold In-Tube (QFT-
GIT) assays, in older adults are limited, but the speciﬁcity for all
ages is greater than the TST when BCG-vaccinated individuals are
tested.8,11,18 For low-risk populations, pooled speciﬁcity esti-
mates range from 93% for T-SPOT.TB to 98% for QFT-GIT,11 and it
appears that IGRA sensitivity is less affected by age than the TST. In
one study, older adults (deﬁned as age greater than 50 years) were
3.8 times as likely to be QFT-GIT-positive/TST-negative as
younger adults.13 Older age was associated with positive IGRA
(but not TST) results in persons screened prior to renal
transplant,19 Japanese healthcare workers,20 and persons with
radiographic evidence of healed TB.21 Similarly, IGRA results were
not affected by age in patients with silicosis22 and in the older
population in the UK (odds ratio 5.3, 95% conﬁdence interval 2.9–
9.8 for IGRA positivity with increasing age).23 This suggests that
with age, the TST response may wane, but the IGRA response
persists.
Persistent immune responses to M. tuberculosis antigens can be
assessed by evaluating antigen-speciﬁc memory cell response
and activation. CD69 is an early activation marker on the surface of
lymphocytes24,25 and a costimulatory molecule for T-cell activa-
tion and proliferation.25,26 The expression of CD69 on CD4+ T-cells
correlates with TST induration, lymphocyte blastogenesis, and
IGRA results.25,27 CD69 has been found in greater amounts on
CD4+ T-cells (after M. tuberculosis antigen stimulation) in persons
who are TST-positive or have clinically inactive/treated TB
compared with those who are TST-negative.25,27,28 It was
therefore predicted that CD69 upregulation could potentially
be used to quantify T-cell activation in vitro to identify infection in
older adults, thereby differentiating ‘true-positive’ from ‘false-
positive’ TST and T-SPOT.TB results.
Given the potential for LTBI reactivation within LTCFs and
spread to other residents, the diagnosis and treatment of LTBI is a
public health priority. The goal of this study was to improve our
understanding of LTBI diagnostics in this population and deter-
mine the relationship between TST responsiveness in older adults,
T-SPOT.TB test results, and immunologic evidence of memory
T-cell response.
2. Methods
2.1. Study location and data collection
This cross-sectional study was performed between September
2011 and August 2012 in three Boston-area LTCFs. Records were
reviewed to identify all HIV-uninfected residents with a history of
a positive TST performed on admission to the facility, or
documented as positive prior to admission as part of the patient’s
routine healthcare. The speciﬁc setting and indication for prior
testing was not always known and was not recorded. Controls with
known prior negative TSTs (and no known positive TST) were
matched to the TST-positive individuals by sex and age (within
5 years). Study personnel performed a medical records review and
administered a standardized questionnaire to participants, or to
the legal authorized representatives (i.e., healthcare proxies) of
those persons without capacity to provide consent. Questionnairesaddressed known history of TB disease, LTBI history, BCG
vaccination, and comorbidities known to be associated with LTBI.
The TST was performed using the Mantoux technique with 2 TU
of puriﬁed protein derivative (Sanoﬁ Pasteur, Cambridge, MA, USA)
and read by trained personnel at 48–72 h; results 10 mm were
considered positive,29 and any questionable result was conﬁrmed
by a second reader. TSTs were repeated (‘boosted’) once after 7–14
days for those persons with an initial negative TST. T-SPOT.TB
assays were performed at the ﬁrst study visit and were processed
by Oxford Immunotech (Marlborough, MA, USA) in accordance
with the manufacturer’s guidelines. Results, interpreted by
subtracting the spot count in the negative control from the spot
count in panels A and B, were reported as positive (>8 spots),
negative (<4 spots), borderline (5–7 spots), or invalid. Blood
samples were collected at the ﬁrst study visit for immunological
assessment.
2.2. Immunological assays
Peripheral blood mononuclear cells (PBMCs), isolated from
peripheral blood by Ficoll density gradient (Sigma-Aldrich, St.
Louis, MO, USA), were cultured in 10% fetal bovine serum in RPMI
1640 supplemented with 2 mM L-glutamine and 1 mM penicillin/
streptomycin (Invitrogen, Woburn, MA, USA). Cells were stimulat-
ed with M. tuberculosis whole cell lysate (WCL) (BEI Resources,
Manassas, VA, USA) for 3 days. Cells were harvested and prepared
for ﬂow cytometry to quantify T-cell activation using anti-CD69,
CD3, CD4, and CD8 antibodies (BD Pharmingen, San Diego, CA,
USA). The positive control for T-cell activation was stimulation
with anti-CD3/CD28 (eBioscience, San Diego, CA, USA); CD3+CD4+
T-cells and CD3+CD8+ T-cells were assessed for expression of CD69
by ﬂow cytometry. Supernatants were analyzed for expression of
interferon-gamma (IFN-g) by ELISA (R&D Systems, Minneapolis,
MN, USA).
2.3. Statistical analyses
All analyses were performed using SAS 9.1.3 (SAS Institute,
Cary, NC, USA). p-Values were calculated using the exact Wilcoxon
two-sample test for continuous variables and Fisher’s exact test for
categorical variables. CD69 expression on CD4+ T-cells and CD8+ T-
cells was analyzed in two ways: (1) percentage expression, and (2)
the ratio of percentage expression following WCL stimulation to
percentage expression following stimulation with media (with a
cut-off of 3 denoted as ‘positive’ CD69 expression). The Institu-
tional Review Board of Boston University approved this study.
3. Results
3.1. Participant characteristics
One hundred and twenty-one persons were screened for
participation and 38 persons were enrolled in the study (31.4%
participation rate). Among the 83 who did not participate, the
reasons for non-participation included legally authorized repre-
sentative unwilling to consent (n = 32, 38.5%), inability to contact
legally authorized representative despite numerous attempts
(n = 19, 22.9%), subject unwilling to consent (n = 18, 21.8%), and
other (n = 14, 16.9%). Laboratory data were not available for one
participant. Among the 37 with data, 29 (78.4%) were male, and the
median age was 77 years (range 57–98 years) (Table 1). Among
those with data on race/ethnicity, 25/33 (75.8%) were black, 8/33
(24.2%) were white, and 5/34 (14.7%) were Hispanic; 12/27 (44.4%)
were born outside the USA. The median duration of residence in
the LTCF was 5 years (range 0–19 years).
Table 1
Demographic characteristics of the study participants (n = 37)
Persons with a history of a positive TST (n = 18) Persons with a history of a
negative TST (n = 19)





















Number 10 3 1 1 2 1 18 1
Median age (range) 77 (60–88) 82 (72–83) 92 80 75.5 (67–84) 83 74 (57–98) 70
Male, n (%) 9 (90%) 3 (100%) 1 (100%) 0 (0%) 1 (50%) 1 (100%) 13 (72.2%) 1 (100%)
Race
Black 8 3 0 1 2 ND 11 1
White 2 0 1 0 0 5 0
Ethnicity
Hispanic 1 0 1 0 0 ND 3 0
Not Hispanic 9 3 0 1 2 14 1
US-born
Yes 2 2 0 1 1 ND 10 ND
No 4 1 1 0 1 5
Median years in LTCF (range)
Previous LTCF 2.25 (0.5–4) 1 0 0 1.5 (1–2) ND 3 (3–3) ND
Current LTCF 4 (1–19) 4 (1–4) 0 7 1 (1–1) 10 6.5 (1–18) 9
Total 4 (1.5–19) 4 (2–4) 0 7 2.5 (2–3) 10 7.5 (1–18) 9
TST, tuberculin skin test; pos, positive; neg, negative; LTCF, long-term care facility; ND, unknown or not documented.
N.S. Hochberg et al. / International Journal of Infectious Diseases 44 (2016) 37–43 393.2. TST/T-SPOT.TB discordance
Of the 18 persons with a prior positive TST, 14 had a persistent
positive TST (two had TSTs 10 and <15 mm, and 12 had TSTs
15 mm) and one boosted positive at the time of the study
(Figure 1). Of the 14 persistent positives, three (21.4%) had a
negative T-SPOT.TB result and one (7.1%) had a borderline positive
T-SPOT.TB result (8 spots). Among the nine with a positive TST and
T-SPOT.TB, the median spot count was >50 (range 16 to >50).
Regarding the likelihood that their initial positive TST was a false-
positive TST, none of the three people with discordant results had
information on previous contact with a TB case. One was born and
had lived much of life in Jamaica, but the participant’s BCG
vaccination status was not known. The other two persons with
discordant results were unlikely to have received BCG vaccine as
they were born in the USA, but they may have had exposure to non-
tuberculous mycobacteria (based on location of residence). The
one participant with a borderline T-SPOT.TB result, born in Puerto
Rico and with unknown BCG vaccination history, had reportedly
previously been treated for TB disease (although the timing and
duration of treatment were unknown).
3.3. TST reversion over time
Of the 18 persons with a history of a positive TST, three (16.7%)
had a negative TST at the time of the study, including two with a
negative T-SPOT.TB (one was missing data) (Figure 1). None of the
three had a TST test result documented at the time of admission to37
18 Histo ry TST +
3 TST-










Figure 1. Flow diagram of tuberculin skin test (TST) and interferon-gamma release assay (
was the T-SPOT.TB test.)the LTCF and none was known to have been a contact of a TB case
prior to arrival at the LTCF. Two may have had false-negative TSTs
at the time of the study, as they had comorbidities that could affect
TST results (rheumatoid arthritis on hydroxychloroquine and
chronic renal disease).
3.4. TST boosting
One person with a history of a positive TST had a negative result
followed by a boosted positive TST at the time of the study (from
0 to 10 mm). This individual, who had lived only in the USA (and
hence had never been BCG-vaccinated), had a history of contact
with a TB case in a family member (at unknown time). The medical
history included diabetes mellitus, chronic renal disease, and
dementia.
3.5. New TST-positive
Nineteen persons with a history of a negative TST (and no
history of a positive TST) were enrolled; of these, one was found to
be TST-positive (but T-SPOT.TB-negative), while the remaining
were TST-negative and T-SPOT.TB-negative (n = 16) or TST-
negative and not tested with T-SPOT.TB (n = 2). For the participant
with a newly positive TST, the ﬁrst recorded TST result was 0 mm,
done 1 year prior to the study. This participant had no information
available on previous TB case contacts, country of birth, previous
places lived, previous BCG vaccine, or homelessness and had a
history of diabetes, chronic obstructive pulmonary disease (COPD), Subjects Enrolled
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IGRA) results for older long-term care facility residents, n = 37. (Note: The IGRA used
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there were no new cases of TB in the LTCF during the study period,
so it is unlikely that the TST conversion was the result of recent
exposure.
3.6. T-cell response
The expression of CD69 on T-cells following PBMC culture with
WCL was measured to determine the relative levels of TB-speciﬁc
T-cell activation. Representative ﬂow cytometry plots are shown in
Figure 2A, demonstrating increased levels of CD69 following
stimulation with the positive control (anti-CD3/CD28) and WCL. T-
cells from all participants who were tested had increased CD69
levels following stimulation with anti-CD3/CD28 (data not shown).
WCL-induced CD69 expression on CD4+ T-cells (Figure 2B) and
CD8+ T-cells (Figure 2C) was higher in patients with a positive TST
and T-SPOT.TB (CD4+ T-cells 18.2%; CD8+ T-cells 14.1%) than in
those who were TST-negative and T-SPOT.TB-negative or T-
SPOT.TB unknown (CD4+ T-cells 5.9%, p = 0.0001; CD8+ T-cells
4.1%, p < 0.0001). CD69 expression on CD4+ T-cells also tended to
be higher in persons with a positive TST and T-SPOT.TB (18.2%)
than in those with a positive TST but negative T-SPOT.TB (6.4%,
p = 0.16) and those with a boosted-positive TST and positive T-
SPOT.TB (4.8%, p = 0.37). CD69 expression on CD8+ T-cells tended
to be higher in persons with a positive TST and T-SPOT.TB (14.1%)
than in those with a positive TST but negative T-SPOT.TB (5.4%,
p = 0.11) and those with a boosted-positive TST but negative T-
SPOT.TB (4.1%, p = 0.18).
CD69 as a ratio measure of expression following stimulation
with WCL compared to stimulation with media was also
evaluated. Those who were TST-positive at the time of the
study (compared to TST-negative) were more likely to be CD69-
positive when deﬁned as a three-fold increase (47% vs. 13%,Figure 2. (a) Representative ﬂow cytometry plots demonstrating the level of CD69 follo
(WCL). (b) CD69 expression on CD4+ T-cells comparing tuberculin skin test (TST)-negativ
TST-positive/IGRA-negative participants. (c) CD69 expression on CD8+ T-cells comparin
negative participants. (Note: The IGRA used was the T-SPOT.TB test.)p = 0.05). Prior positive TST status (compared to prior TST-
negative) was not associated with current CD69 response (40%
vs. 18%, p = 0.24). The one individual with a boosted TST
response was not CD69-positive as deﬁned above (their ratio of
WCL/media was 2.25). Current T-SPOT.TB-positive status (com-
pared to current T-SPOT.TB-negative) was not associated with a
positive CD69 response (36% vs. 19%, p = 0.39).
CD69 expression on CD4+ T-cells following stimulation with
WCL was found to be correlated with TST induration in
millimeters (r = 0.76621, p < 0.0001) and T-SPOT.TB values as
a continuous measure (r = 0.68614, p < 0.0001) (Figure 3A, B).
CD69 expression on CD8+ T-cells following stimulation
with WCL was found to be correlated with TST positivity
(r = 0.76767, p < 0.0001) and with T-SPOT.TB values (r = 0.61287,
p = 0.0003).
4. Discussion
This study of diagnostic testing for LTBI in the older LTCF
population demonstrated that testing is complicated by TST
reversion over time and TST-positive/T-SPOT.TB-negative dis-
cordance. Almost a ﬁfth of participants with a prior positive TST
had reverted to a negative TST at the time of this study. Such
reversions may reﬂect clearance of infection (or lack of infection
in the past) or false-negative reactions due to an impaired
response to the test. Furthermore, a third of participants with a
history of a positive TST and a persistently positive TST had a
negative or borderline T-SPOT.TB test. Based on T-cell CD69
responses, it is possible that reversion and discordance may
reﬂect clearance of infection.
To improve our understanding of diagnostic testing for LTBI in
older adults, we must address three critical questions. First, what
proportion of TST-positive responses revert over time and whatwing stimulation with the positive control (anti-CD3/CD28) and whole cell lysate
e/interferon-gamma release assay (IGRA)-negative, TST-positive/IGRA-positive, and
g TST-negative/IGRA-negative, TST-positive/IGRA-positive, and TST-positive/IGRA-
Figure 3. CD69 expression on CD4 correlations with (a). tuberculin skin test (TST) and (b). interferon-gamma release assay (IGRA) results. (Note: The IGRA used was T-SPOT.TB
test.)
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participants with a history of a prior positive TST no longer had a
positive TST at the time of the study. These ﬁndings are consistent
with a previous report that 9% of persons 60 years of age revert
their TST annually.16 Reversions are more common in persons with
a smaller initial TST reaction;30 however, the present study was
limited by not having the initial TST size for the participants.
Reversions suggest the possibility of cleared infection, the lack of
ability to mount an immune response, or that the ﬁrst TST was a
false-positive. To assess the immunologic response to infection
(and whether those whose TST reverted had cleared their
infections), the CD69 response was evaluated. It was found that
merely having a history of a positive TST was not associated with a
current positive CD69 response. The fact that fewer T-cells are
activated in these individuals suggests that reversion of the TST
may reﬂect clearance of infection or waning immunity; these
ﬁndings are supported by the negative T-SPOT.TB in these same
individuals. In a 19-year follow-up study of 20 TST-positive
persons, 10% reverted their TST despite a booster;31 those who
reverted had a poor blastogenic response, suggesting cleared
infection. It is also possible, however, that those individuals with
TST reversion in the present study were merely not able to mount
an immune response; medical conditions (rheumatoid arthritis,
end-stage renal disease) could have blunted the immune response
in two-thirds whose TST reverted.32–34 On the other hand, none
had developed active TB despite this immunosuppression, so this
makes it more likely that infection had been eliminated. A third
explanation for the reverted TST, that the persons were never in
fact truly infected (i.e., the previous positive test was a false-
positive), is possible as none of those in the present study were
known to be contacts of TB cases or to have had prior TB disease.
Hence, the reversion of TSTs over time can complicate their
interpretation.
The second key question when considering diagnostic testing
for LTBI in older adults is how to interpret a sustained positive TST
response. Does this reﬂect persistent infection and necessitate
treatment? It was found that the magnitude of TST induration at
the time of the study was correlated with the CD69 response and
that those with a positive TST at the time of the study had a positive
CD69 response (deﬁned as a three-fold increase compared to
media stimulation alone). These ﬁndings suggest that sustained
positive TSTs may represent true infection as indicated by a
sustained T-cell response. Notably, however, the one person with a
new positive TST had a negative T-SPOT.TB and little evidence of a
cellular immune response to M. tuberculosis. False-positive TST
reactions could be explained by exposure to non-tuberculous
mycobacteria, BCG vaccination (although less likely given the ageof the participants), or potentially by other undetermined test
characteristics in older adults.8–10 False-positive TSTs not only
result in possible treatment of individuals who are in fact not
infected with M. tuberculosis (and the associated cost and
medication side effects), but also the potential for increased
testing of other facility residents and staff. Further immunologic
studies are warranted to determine the true nature of a sustained
(or new positive) TST response to understand which individuals
require treatment.
The third key diagnostic question in this population is the
signiﬁcance of a boosted positive TST. In the present study, only
one participant had a boosted positive TST and had little
evidence of a cellular response to M. tuberculosis antigens. It is
plausible that the boosted TST was a false-positive. This ﬁnding
is in concordance with the results of a large-scale longitudinal
study of LTCF residents in Hong Kong, which found that one-step
but not two-step TST results predicted future TB disease.12 At all
cut-off points, two-step testing had greater sensitivity but less
speciﬁcity than one-step testing. Others have reported that
increasing the boosted test cut-off decreases false-positive
reactions and is more predictive of developing disease.30
Boosting is common among older persons with an initial
reading between 5 and 9 mm,15,35,36 and persons with a weak
(varyingly deﬁned as <10, <12, or <15 mm) boosted TST
response are signiﬁcantly more likely to revert on re-test.31,33,37
Studies have shown that 12–13% of persons sensitized to non-
tuberculous mycobacteria demonstrate boosting.30 Hence, the
use of boosted testing in the older LTCF population may result
in more ‘false-positives’, with the associated drawbacks of
unnecessary treatment.
Testing CD69 expression may be a useful adjunct to
understanding TST and T-SPOT.TB results, particularly in
conjunction with more targeted immunologic assays. It is likely
that CD69 measures a different pathway for M. tuberculosis
infection than does the T-SPOT.TB, because to the authors’
knowledge, CD69 is not an IFN-g-inducible gene product. A good
correlation was found between the in vitro tests for CD69
expression and separately TST and T-SPOT.TB response—sup-
porting earlier ﬁndings that CD69 expression correlates with
M. tuberculosis infection status.25,27 The present immunologic
assays were limited in their capacity to evaluate T-cells
speciﬁcally, due to the use of PBMCs in culture and the
relatively low volume of blood collected.
This study has several limitations. First, the lack of a true gold
standard for M. tuberculosis infection limits the interpretation of
test results. Second, the study was limited by the small sample
size; however, the inclusion of immunologic parameters enhances
N.S. Hochberg et al. / International Journal of Infectious Diseases 44 (2016) 37–4342the interpretation of the diagnostic test results. Third, it was not
possible to verify the historical TST results collected prior to LTCF
admission or to determine the reason for prior testing, but this lack
of data mirrors what is seen in clinical practice, as one rarely has
access to historical TST data when evaluating present day test
results. Lastly, the interpretation of the ﬁndings is potentially
limited because of antigenic differences between WCL (for CD69
expression), T-SPOT.TB, and TST, as antigens in WCL are not as
speciﬁc for M. tuberculosis as those in the T-SPOT.TB.
In summary, this study suggests that diagnostic testing for LTBI
in the older adult population is complicated by TST reversions, TST/
T-SPOT.TB discordance, and a lack of clear immunologic correlates
of infection. The CD69 analyses suggest the possibility that the
reverted TST responses may reﬂect cleared infection, but
additional immunologic analyses are needed. Accurate diagnosis
of LTBI in older adults, particularly LTCF residents, is important
given the potential public health implications of disease reactiva-
tion and spread within facilities. Although LTBI treatment of older
adults must balance factors that increase the risk of reactivation
(e.g., diabetes, use of tumor necrosis factor alpha (TNF-a)
inhibitors, immunosuppression) and those that might complicate
treatment (e.g., underlying liver disease),38 as new shorter and
better-tolerated regimens become available, the balance may shift
in favor of treatment.
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